Hints and tips:
Related Special Reports
...’s Astellas Pharma on espionage charges....
...Astellas Pharma bought eye-treatment specialist Iveric Bio in a $5.9bn deal in May. Mizuho splashed out $550mn for US boutique investment bank Greenhill & Co....
...Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market for age-related...
...Chinese authorities detained a local senior Astellas executive in Beijing last month as he was about to board a flight back to Japan....
...Japan has said 17 of its citizens have been detained since China passed a counter-espionage law in 2014, of whom five remain in detention, including an executive of Astellas Pharma who was taken into custody...
...Biotech business Redx Pharma this week blamed low liquidity on London’s junior market for its decision to delist its shares from Aim and re-register as a private company....
...It will acquire the rights to sell it in the US, where there is a $15bn market for IBD, and in Japan....
...’s Astellas Pharma group and hit London-headquartered Deloitte with a record fine....
...It has also raided US due diligence firm Mintz and Bain, the consultancy, and detained an executive from Japan’s Astellas Pharma group....
...’s Astellas Pharma group....
...Pharma; levied a record fine against Deloitte, and amended its espionage law to cover ordinary business activities....
...Olczak last month pointed to the success of countries like Japan and Sweden in switching smokers from cigarettes to alternatives. Reduced- harm options are controversial but present fewer health risks....
...US biotech group Iveric Bio is being bought by Astellas Pharma, marking the latest acquisition by Japanese companies seeking growth outside their home market....
...Japan’s Astellas Pharma is to buy US biotech Iveric Bio for $5.9bn, its largest-ever acquisition which gives it access to the rapidly growing market for age-related eye diseases....
...In March, the state also detained without explanation five local employees of US due diligence firm Mintz Group and arrested a Japanese worker at pharmacy company Astellas Pharma on allegations of espionage...
...The company said it would now apply for full approval in the US, Japan and Europe....
...He said J&J and Legend had consulted extensively with the FDA for its trials, which initially took place in China but later expanded to the US and Japan....
...The initial portfolio is heavy with drug and biotech companies, such as Japan’s Astellas Pharma, Germany’s Fresenius Medical Care and Biogen of the US....
...Alex Rowe, portfolio manager at Japan-based Nomura Asset Management, said “prioritising access to vaccines over near-term profits is not only the right thing to do from an ethical standpoint, but the most...
...It also began a smaller-scale clinical trial this month in Japan, where it hopes to apply for regulatory approval by March....
...Japan Inc stages a Covid comeback While the past few years have heralded a dealmaking boom that started a pay revolution on Wall Street, a talent war in Big Law and boosted the bottom lines of banks on...
...Annual jabs would increase the size of the Covid vaccine market across seven major markets — the US, Germany, France, Italy, Spain, UK and Japan — from $13.6bn in 2021 to $19.5bn in 2026, according to GlobalData...
...The new J&J, compromising the pharma and medical devices units, and a standalone consumer business would each be more nimble and dynamic, she added....
...The line between the pharma and tobacco sectors isn’t as crisp as you might assume: Japan Tobacco has a pretty small pharma division which dates back to the 1980s; GSK works with a company called Medicago...
...UMN Pharma now stands in negative net worth and under the wing of fellow Japanese pharma company Shionogi....
International Edition